Transforming Technology for Drug Discovery |
HOME | ABOUT US | TECHNOLOGY | OUR SERVICE | PUBLICATIONS | CONTACT US |
Ligandomics technology was recently published in the prestigious Journal of Experimental Medicine Secretogranin III as a disease-associated ligand for anti-angiogenic therapy of diabetic retinopathy. J. Exp. Med. 214(4):1029-1047 The innovation and breakthrough nature of this approach are highlighted by the press release from the Journal at http://www.newswise.com/articles/view/671627/?sc=rsin. |
© Copyright LigandomicsRx. All rights reserved. |